Alport Syndrome Epidemiology Forecast, Diagnosis, Treatment Options | DelveInsight

April 04 04:00 2020
Alport Syndrome Epidemiology Forecast, Diagnosis, Treatment Options | DelveInsight

‘Alport Syndrome – Epidemiology Forecast to 2030’

 

DelveInsight launched a new report on ‘Alport Syndrome – Epidemiology Forecast to 2030’.

DelveInsight’s ‘Alport Syndrome – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Alport Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Some of the facts of the report

1. Alport syndrome occurs in approximately 1 in 50,000 newborns.
2. Alport syndrome is estimated to account for 3% of children with chronic kidney disease and 0.2% of adults with end-stage renal disease in the United States.
3. Alport Syndrome is estimated to affect approximately 1 in 5,000-10,000 people in the general population in the United States.

“According to DelveInsight, Alport syndrome primarily affects men.”

Alport Syndrome (also referred to as hereditary nephritis) is an inherited progressive form of glomerular disease that is often associated with sensorineural hearing loss and ocular abnormalities. Patients with Alport Syndrome will experience progressive loss of kidney function. Almost all patients experience blood in their urine (hematuria) as well as proteinuria at symptom onset. The kidneys lose function as this condition progresses, resulting in kidney failure. There are three genetic Sub-divisions. X-linked Alport Syndrome (XLAS) is the most common; in these families affected males typically have more severe disease than affected females.

In autosomal recessive Alport Syndrome (ARAS) the severity of disease in affected males and females is similar. There is also an autosomal dominant form (ADAS) that affects males and females with equal severity. Alport Syndrome is caused by mutations in specific genes.

People with Alport Syndrome frequently develop sensor neural hearing loss, which is caused by abnormalities of the inner ear, during late childhood or early adolescence. Affected individuals may also have misshapen lenses in the eyes (anterior lenticonus) and abnormal coloration of the light- sensitive tissue at the back of the eye (retina). These eye abnormalities seldom lead to vision loss.

“According to DelveInsight, Significant hearing loss, eye abnormalities, and progressive kidney disease are more common in males with Alport Syndrome than in affected females. “

Request for sample pages : https://www.delveinsight.com/sample-request/alport-syndrome-epidemiology-forecast

 

Scope of the Report

  • The Alport Syndrome report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Alport Syndrome Epidemiology Report and Model provide an overview of the risk factors and global trends of Alport Syndrome in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Alport Syndrome in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Alport Syndrome
  • The report provides the segmentation of the Alport Syndrome epidemiology

 

KOL- Views

We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

 

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Alport Syndrome?
  • What are the key findings pertaining to the Alport Syndrome epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Alport Syndrome across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Alport Syndrome?
  • What are the currently available treatments of Alport Syndrome?

 

Request for sample pages : https://www.delveinsight.com/sample-request/alport-syndrome-epidemiology-forecast

 

Reasons to buy

  • The Alport Syndrome Epidemiology report will allow the user to –
  • Develop business strategies by understanding the trends shaping and driving the global Alport Syndrome market
  • Quantify patient populations in the global Alport Syndrome market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Alport Syndrome therapeutics in each of the markets covered
  • Understand the magnitude of Alport Syndrome population by its epidemiology
  • The Alport Syndrome Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

 

Related Reports:

Alport Syndrome – Pipeline Insights, 2020

The Alport Syndrome report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Alport Syndrome across the complete product development cycle, including all clinical and nonclinical stages.

Alport Syndrome – Market Insights, Epidemiology, and Market Forecast-2030

The Alport Syndrome market report provides current treatment practices, emerging drugs, Alport Syndrome market share of the individual therapies, current and forecasted Alport Syndrome market Size from 2017 to 2030 segmented by seven major markets. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/giridihjournal.in/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7
  Categories: